Skip to main content
Andrea Apolo, MD, Oncology, Bethesda, MD

AndreaBorgheseApoloMD

Oncology Bethesda, MD

Genitourinary Oncology, Hematologic Oncology

Chief, Bladder Cancer Section, Genitourinary Malignancies Branch Center for Cancer Research, National Cancer Institute, National Institutes of Health

Dr. Apolo is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Apolo's full profile

Already have an account?

  • Office

    10 Center Dr Rm 12n226
    Bethesda, MD 20892
    Phone+1 301-480-0536

Summary

  • Dr. Apolo is dedicated to improving the treatment and survival of patients with genitourinary tumors. Her research involves developing and designing clinical trials to test novel agents for the treatment of urologic cancers. Her primary research interest is in bladder cancer (urothelial carcinoma) and prostate cancer. In particular, she is working to develop new bladder cancer therapies that use targeted agents including anti-angiogenesis compounds, which block the growth of new blood vessels that feed tumors. Other research focuses include improving tumor detection by using new imaging modalities in bladder and prostate cancer and identifying molecular alterations in bladder tumors that will serve as targets for individualized treatment strategies in patients with this disease.

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2003 - 2006
  • Albert Einstein College of Medicine
    Albert Einstein College of MedicineClass of 2003

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2006 - 2025

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Circulating tumor cell (CTC) enumeration in patients (pts) with metastatic genitourinary (mGU) tumors treated in a phase I study of cabozantinib and nivolumab (CaboNiv... 
    2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

  • Atezolizumab Does Not Demonstrate Significant OS Benefit Compared with Chemotherapy in Untreated Locally Advanced or Metastatic Urothelial Cancer
    Atezolizumab Does Not Demonstrate Significant OS Benefit Compared with Chemotherapy in Untreated Locally Advanced or Metastatic Urothelial CancerFebruary 26th, 2023
  • Exploratory Data for Treatments in Advanced Bladder Cancer - Joaquim Bellmunt
    Exploratory Data for Treatments in Advanced Bladder Cancer - Joaquim BellmuntJanuary 31st, 2023
  • Sex After Bladder Cancer
    Sex After Bladder CancerMay 4th, 2022
  • Join now to see all